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background: Most acute heart failure (AHF) patients have dyspnea but their most bothersome (worst) symptom (WS) may vary. We hypothesized 
that improvement in a patient’s WS over time would be associated with decongestion efficacy and outcomes in AHF.
Methods: Patients with AHF enrolled (< 24 hr from admission) in ROSE-AHF identified their WS at enrollment (BL) and completed a WS (WS-VAS) 
and dyspnea (DVAS) visual analogue scale at BL, 24, 48 and 72 hr. Clinical decongestion at 72 hrs (weight change (Δ), cumulative urine volume and 
% Δ in NT-proBNP) and 60-day outcomes (death/HF rehospitalization) were assessed.
results: The WS was dyspnea in 61% (n=141), body swelling (BS) in 29% (n=67) and fatigue in 10% (n=24). Clinical characteristics, BL WS-VAS 
and BL DVAS differed by WS (Table). The mean (SD) change over 72 hrs in WS-VAS (22.1 ± 26.1) was greater than the change in DVAS (16.5 ± 25.8; 
p<0.001). The time course and degree of improvement in WS-VAS or DVAS did not differ by WS. There were no significant associations between WS-
VAS (BL or 72 hrs) or Δ in WS-VAS over 72 hrs and decongestion efficacy or outcomes.
conclusions: Here, 40% of AHF patients reported symptoms other than dyspnea as their WS and these patients had unique clinical profiles. While 
a WS-specific VAS showed greater change over 72 hrs, WS relief was not associated with the extent of decongestion during AHF hospitalization or 
post-discharge outcomes. Better metrics for assessing efficacy of AHF treatment are needed.
Median values or % shown Dyspnea (n=141) Body Swelling (n=67) Fatigue (n=24)
Age 68 71 72
HF duration (years) 4.0 5.0 7.0*
Ischemic etiology (%) 58% 43%* 54%
Atrial fibrillation (%) 52% 64% 75%*
Moderate or Severe Tricuspid Regurgitation (%) 36% 62%* 88%*
Systolic Blood Pressure (mmHg) 117 114 114
Heart rate (bpm) 80 74* 72*
Rales (%) 59% 44%* 52%
3-4+ Edema (%) 33% 50%* 33%
Orthopnea (%) 81% 62%* 56%*
Glomerular Filtration Rate (ml/min/1.73m2) 45 42* 49
BL Dyspnea VAS (0 worst, 100 best) 54 75* 77*
BL Worst Symptom VAS (0 worst, 100 best) 54 33* 52
* p<0.05 vs Dyspnea as WS
